You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation

https://doi.org/10.1136/ebm.11.6.170

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The ACTIVE Writing Group on behalf of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–12.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients with atrial fibrillation (AF), is clopidogrel plus aspirin non-inferior to oral anticoagulation for preventing vascular events?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ Haematology ★★★★★★★

    METHODS

    Embedded ImageDesign:

    randomised controlled trial (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events [ACTIVE W]).

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded (outcome assessors and monitoring committee).*

    Embedded ImageFollow up period:

    median 1.28 years.

    Embedded ImageSetting:

    30 clinical centres worldwide.

    Embedded ImagePatients:

    6706 patients (mean age 70 y, 66% men) with AF and ⩾1 of the following criteria: age ⩾75 years; receiving treatment for systemic hypertension; previous stroke, transient ischaemic attack, or non-central nervous system (non-CNS) systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; peripheral arterial disease; or age 55–74 years with diabetes mellitus requiring drug therapy …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • Sources of funding: Sanofi Aventis and Bristol Myers Squibb.

      Sources of funding: Sanofi-Aventis and Bristol-Myers Squibb

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 191-191 Published Online First: 30 Nov 2006. doi: 10.1136/ebm.11.6.191-a